Iga Nephropathy
📧 Sign up to get email alerts when something new happens for Iga Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-07-04Clinical Trial Update: An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy [EARLY_Phase 1]
An exploratory early-phase clinical trial of an anti-CD19/BCMA CAR NK cell therapy for IgA nephropathy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-20Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G [Phase 2]
Phase 2 trial of ADX-097 for IgA nephropathy, lupus nephritis, and C3 glomerulopathy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-04-05Clinical Trial Update: Acthar on Proteinuria in IgA Nephropathy Patients [Phase 4]
A Phase 4 trial evaluating Acthar for proteinuria in IgA nephropathy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-10-23Clinical Trial Update: Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy [Phase 2]
Phase 2 open-label study of fostamatinib for IgA nephropathy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-08-03Clinical Trial Update: Paricalcitol for the Treatment of Immunoglobulin A Nephropathy [Phase 3]
Phase 3 trial evaluating paricalcitol for immunoglobulin A nephropathy has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-07-30Clinical Trial Update: BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy [Phase 3]
Anthera Pharmaceuticals has withdrawn the Phase 3 BRILLIANT-SC trial evaluating blisibimod for IgA nephropathy.